We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates
Read MoreHide Full Article
Key Takeaways
CRISPR Therapeutics reported a wider Q4 loss of $1.37 per share and revenues of $0.9M, missing estimates.
CRSP's partner Vertex logged $54M Q4 Casgevy sales, up from $16.9M, with momentum seen into 2026.
CRISPR plans 2026 Casgevy label filings and advances CAR-T, in-vivo and RNA programs with updates due.
CRISPR Therapeutics (CRSP - Free Report) reported a fourth-quarter 2025 loss of $1.37 per share, wider than the Zacks Consensus Estimate of a loss of $1.15. The company had incurred a loss of 44 cents per share in the year-ago quarter.
Total revenues, comprising only grant revenues, amounted to $0.9 million in the quarter, which significantly missed the Zacks Consensus Estimate of $4.0 million. In the year-ago period, CRISPR Therapeutics recorded total revenues of $35.7 million, which included $35 million in collaboration revenues received from partner Vertex Pharmaceuticals (VRTX - Free Report) .
CRSP Stock Movement
Shares of CRISPR Therapeutics were down in after-market trading yesterday, likely due to the wider-than-expected loss incurred during the quarter.
In the past year, the stock has risen nearly 13% compared with the industry’s 19% growth.
Image Source: Zacks Investment Research
CRSP Boasts Robust Casgevy Sales Outlook
CRISPR Therapeutics and partner Vertex Pharmaceuticals’ CRISPR/Cas9 gene therapy, Casgevy, is approved across the United States and Europe for two blood disorder indications — sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Per the deal terms, Vertex leads global development, manufacturing and commercialization of Casgevy, and splits program costs and profits worldwide with CRISPR Therapeutics in a 60:40 ratio.
Vertex recorded Casgevy sales of $54 million in the fourth quarter, up from $16.9 million in the previous quarter. With this, VRTX has recorded $116 million in full-year 2025 sales of the therapy, driven by patient initiations and first cell collections that rose about three times compared to 2024 levels. CRISPR Therapeutics expects this momentum to continue in 2026, backed by continued uptake for therapy and reimbursement progress across major regions.
More on CRSP’s Results
Research and development (R&D) expenses rose 16% year over year to $83.5 million, driven by an increase in licensing fees. General and administrative expenses were up about 2% to $18.4 million in the quarter.
CRISPR Therapeutics reported net collaboration expense of $53.7 million in the quarter compared with $10.4 million recorded in the year-ago period. In the year-ago period, the company had exercised an option to defer specified costs under the Casgevy program. The uptick in expenses reflects the absence of a comparable deferral in 2025.
As of Dec. 31, 2025, the company had cash, cash equivalents and marketable securities worth $1.98 billion compared with $1.94 billion as of Sept. 30, 2025. This rise in cash was primarily due to proceeds from the issuance of common shares.
CRSP’s Pipeline Updates
Vertex and CRISPR have planned regulatory submissions seeking label expansion for Casgevy in patients aged five to 11 years with SCD and TDT in the first half of 2026. For the FDA submission, Vertex intends to use the Commissioner’s National Priority Voucher to significantly cut down the review period to 1-2 months.
CRISPR Therapeutics is pursuing the development of CRISPR candidates to create novel CAR-T cell therapies. One such candidate is zugo-cel, which is being evaluated for both autoimmune disease and hematologic malignancies across multiple early-stage studies. Updates on these studies are expected in the second half of 2026.
CRISPR Therapeutics is also focusing on in-vivo candidates. It is currently prioritizing the development of CTX310, designed to target ANGPTL3, in an early-stage study for severe hypertriglyceridemia (sHTG) and refractory hypercholesterolemia. An update on this study is expected in the second half of 2026.
The collaboration with Sirius Therapeutics has helped the company diversify its pipeline beyond gene therapies and into RNA therapeutics. Both companies are developing an investigational RNA therapy called CTX611 (formerly SRSD107), in a mid-stage study for the prevention of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty (TKA). Top-line data from this study are expected in the second half of 2026. CRISPR and Sirius have also expanded the drug’s development to a range of thromboembolic and clotting-related indications, including atrial fibrillation (AF) and chronic kidney disease (CKD).
CRSP’s Zacks Rank
The stock currently carries a Zacks Rank #3 (Hold).
EPS estimates for Alkermes’ 2025 have increased from $2.00 to $2.02, while those for 2026 have risen from $1.80 to $1.91 in the past 30 days. ALKS stock has declined nearly 8% in the past year.
Alkermes’ earnings beat estimates in three of the trailing four quarters and missed the mark on one occasion, delivering an average surprise of 4.58%.
In the past 60 days, estimates for Castle Biosciences’ loss per share have improved from 34 cents to 29 cents for 2025. During the same time, loss estimates for 2026 have narrowed from $1.11 to 96 cents. In the past year, shares of CSTL have risen 16%.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed the mark on one occasion, delivering an average surprise of 66.11%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates
Key Takeaways
CRISPR Therapeutics (CRSP - Free Report) reported a fourth-quarter 2025 loss of $1.37 per share, wider than the Zacks Consensus Estimate of a loss of $1.15. The company had incurred a loss of 44 cents per share in the year-ago quarter.
Total revenues, comprising only grant revenues, amounted to $0.9 million in the quarter, which significantly missed the Zacks Consensus Estimate of $4.0 million. In the year-ago period, CRISPR Therapeutics recorded total revenues of $35.7 million, which included $35 million in collaboration revenues received from partner Vertex Pharmaceuticals (VRTX - Free Report) .
CRSP Stock Movement
Shares of CRISPR Therapeutics were down in after-market trading yesterday, likely due to the wider-than-expected loss incurred during the quarter.
In the past year, the stock has risen nearly 13% compared with the industry’s 19% growth.
Image Source: Zacks Investment Research
CRSP Boasts Robust Casgevy Sales Outlook
CRISPR Therapeutics and partner Vertex Pharmaceuticals’ CRISPR/Cas9 gene therapy, Casgevy, is approved across the United States and Europe for two blood disorder indications — sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Per the deal terms, Vertex leads global development, manufacturing and commercialization of Casgevy, and splits program costs and profits worldwide with CRISPR Therapeutics in a 60:40 ratio.
Vertex recorded Casgevy sales of $54 million in the fourth quarter, up from $16.9 million in the previous quarter. With this, VRTX has recorded $116 million in full-year 2025 sales of the therapy, driven by patient initiations and first cell collections that rose about three times compared to 2024 levels. CRISPR Therapeutics expects this momentum to continue in 2026, backed by continued uptake for therapy and reimbursement progress across major regions.
More on CRSP’s Results
Research and development (R&D) expenses rose 16% year over year to $83.5 million, driven by an increase in licensing fees. General and administrative expenses were up about 2% to $18.4 million in the quarter.
CRISPR Therapeutics reported net collaboration expense of $53.7 million in the quarter compared with $10.4 million recorded in the year-ago period. In the year-ago period, the company had exercised an option to defer specified costs under the Casgevy program. The uptick in expenses reflects the absence of a comparable deferral in 2025.
As of Dec. 31, 2025, the company had cash, cash equivalents and marketable securities worth $1.98 billion compared with $1.94 billion as of Sept. 30, 2025. This rise in cash was primarily due to proceeds from the issuance of common shares.
CRSP’s Pipeline Updates
Vertex and CRISPR have planned regulatory submissions seeking label expansion for Casgevy in patients aged five to 11 years with SCD and TDT in the first half of 2026. For the FDA submission, Vertex intends to use the Commissioner’s National Priority Voucher to significantly cut down the review period to 1-2 months.
CRISPR Therapeutics is pursuing the development of CRISPR candidates to create novel CAR-T cell therapies. One such candidate is zugo-cel, which is being evaluated for both autoimmune disease and hematologic malignancies across multiple early-stage studies. Updates on these studies are expected in the second half of 2026.
CRISPR Therapeutics is also focusing on in-vivo candidates. It is currently prioritizing the development of CTX310, designed to target ANGPTL3, in an early-stage study for severe hypertriglyceridemia (sHTG) and refractory hypercholesterolemia. An update on this study is expected in the second half of 2026.
The collaboration with Sirius Therapeutics has helped the company diversify its pipeline beyond gene therapies and into RNA therapeutics. Both companies are developing an investigational RNA therapy called CTX611 (formerly SRSD107), in a mid-stage study for the prevention of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty (TKA). Top-line data from this study are expected in the second half of 2026. CRISPR and Sirius have also expanded the drug’s development to a range of thromboembolic and clotting-related indications, including atrial fibrillation (AF) and chronic kidney disease (CKD).
CRSP’s Zacks Rank
The stock currently carries a Zacks Rank #3 (Hold).
CRISPR Therapeutics AG Price
CRISPR Therapeutics AG price | CRISPR Therapeutics AG Quote
Our Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are Alkermes (ALKS - Free Report) and Castle Biosciences (CSTL - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
EPS estimates for Alkermes’ 2025 have increased from $2.00 to $2.02, while those for 2026 have risen from $1.80 to $1.91 in the past 30 days. ALKS stock has declined nearly 8% in the past year.
Alkermes’ earnings beat estimates in three of the trailing four quarters and missed the mark on one occasion, delivering an average surprise of 4.58%.
In the past 60 days, estimates for Castle Biosciences’ loss per share have improved from 34 cents to 29 cents for 2025. During the same time, loss estimates for 2026 have narrowed from $1.11 to 96 cents. In the past year, shares of CSTL have risen 16%.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed the mark on one occasion, delivering an average surprise of 66.11%.